In this episode, Ayesha discussed the FDA authorization of Novavax’s COVID-19 vaccine, making it the fourth authorized/approved COVID vaccine in the US. It is also the first protein-based COVID-19 vaccine to be authorized in the country. While the vaccine offers an alternate option to people who may still be hesitant about mRNA vaccines, hear why some experts think it won’t have much of an impact on those who are choosing to remain unvaccinated.
Ayesha also talked about the expanded label approval of Horizon Therapeutics’ gout medication Krystexxa to include its co-administration with arthritis and chemotherapy drug methotrexate. The new approved combination is indicated for the treatment of uncontrolled gout, a rare condition in which patients fail to respond to conventional treatments due to problems including drug resistance. Hear more about gout and the rare condition of uncontrolled gout in this episode.
Read the full articles here:
Novavax Vaccine Becomes First FDA-Authorized Protein Vaccine for COVID-19
Krystexxa Chronic Gout Medication Gets Expanded FDA Approval
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Join or login to leave a commentJOIN LOGIN